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Degree of clinical efficacy
Clinical applicability
Evidence data in regard to harm and costBasic principles for preparing the ‘‘Clinical Practice
Guidelines for Nursing- and Healthcare-associated Pneu-
monia (NHCAP)’’1. Objective: The objective of preparing the Guidelines was to
improve the quality of NHCAP diagnosis, promote public
health, and inform healthcare professionals engaged in
its treatment.2. Reliability: The Guidelines will be made available on the
Japanese Respiratory Society website to collect opinions
from the public and achieve greater reliability.3. Clarity: The important information is listed in a clear and
concise fashion, and commentary and annotations are
provided below.4. Applicability: A variety of clinical states of NHCAP
patients are postulated to enable broad application.5. Flexibility: Consideration is given to enable reasonable
application of the content of the Guidelines. Recommenda-
tions are also made in regard to the handling of excep-
tions, alternative treatments, and unsuccessful cases.6. These Guidelines are intended for use by healthcare
providers who offer NHCAP clinical practice that is
covered by Japanese National Health Insurance, and,
when patients are admitted to ‘‘general beds’’ in Japanese
hospitals.7. The Guidelines should not cause any disadvantages to
anyone. It should be noted that the Guidelines are not
intended to limit clinical practice that is based on superior
clinical experience. These Guidelines are intended to be
references for clinical practice in relation to NHCAP and are
not intended to obligate healthcare practitioners to follow
them precisely in their healthcare practice.8. Conformity: These Guidelines have been prepared in con-
formity with other guidelines for NHCAP and respiratory
infection.9. Recommended medications: Drug groups are recom-
mended according to the nature of each treatment and
the names of typical drugs are listed according to theirFig. 1 – Mortality from pneumonia by age and gender (per 100,0pharmacological actions and actual manner in which
they are used in medical practice.10. Research plans: Information will be collected from surveys,
studies, and papers that are relevant to these Guidelines.11. Future plans: Revisions will be made as needed. In principle,
revisions will be made every five years based on the results
of nationwide surveys, etc. The Japanese Respiratory Society
set up a committee for preparation of these Guidelines, to
collect opinions in regard to these Guidelines from academic
members of the Society, and to focus attention on interna-
tional guidelines and their trends, as well as the intentions
of the Society’s Guidelines Control Committee.1. Forward–concepts of NHCAP and guideline
principles
1.1. Concepts of NHCAP
The mortality rate of pneumonia is 1000 times higher among
the elderly 85 years of age and over than among young adults
irrespective of gender (Fig. 1) [1], and pneumonia is the first
leading cause of death of males 90 years of age and over.
The Japanese Respiratory Society published guidelines for
the management of community-acquired pneumonia (CAP)
in 2000 and guidelines for the management of hospital-
acquired pneumonia (HAP) in 2002 (revised edition published
in 2007 and 2008, respectively [2,3] with the aim of supporting
the management of pneumonia, whose morbidity and mor-
tality rates in the elderly are high.
However, these earlier guidelines did not always play an
adequate role as standards for clinical practice in regard to
elderly patients, who have a high morbidity rate, because
elderly pneumonia patients may be classified as having both
CAP and HAP due to the fact that they are often admitted to
healthcare-related facilities, such as nursing homes, that are
intermediate between hospitals and communities, and
because the outcome of pneumonia in the elderly population
is worse than its outcome in the younger population.
The issues related to the handling of HAP and CAP are not
limited to Japan. The American Thoracic Society (ATS) and
the Infectious Diseases Society of America (IDSA) made
recommendations in regard to the treatment of such00 patients) according to FY2005 vital statistics data.
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the HAP guidelines [4] that they published jointly in 2005.
However, the meaning of ‘‘HC’’ (healthcare) in the guidelines
jointly published by the ATS and IDSA is not always the same as
in Japan; the Japanese healthcare system is characterized by
universal nursing-care insurance for those 65 years of age and
over and by universal health insurance for the entire population,
it is important to create a Japanese version of HCAP guidelines
that includes both nursing-care-associated pneumonia and
healthcare-associated pneumonia.
1.2. Objective and principles of the NHCAP guidelines
Ever since its preparation and publication of the clinical
practice guidelines for CAP and HAP, the constant objective
of the Japanese Respiratory Society in preparing clinical
practice guidelines for pneumonia has been ‘‘to improve the
quality of clinical practice in regard to pneumonia and to
improve public health’’.
Host factors play an important role in improving the quality
of clinical practice in regard to pneumonia. In particular, the
NHCAP population in Japan is quite varied, and it is not a
uniform population because it includes patients who are in
healthcare facilities for the elderly, patients who are receiving
home care, and patients who have been admitted to long-
term care facilities, and because the risks of aspiration
pneumonia and underlying diseases change with age.
In addition, since the NHCAP population also includes patients
who are in their final years of life, such as patients with end-
stage cancer, palliative care as well as long-term outcome is an
important objective of treatment in the NHCAP population.
Strict priority in deciding where NHCAP patients are to be
treated should be given to the judgments made by patients
themselves, their physicians, and family members who
provide their nursing care, and these Guidelines will not touch
on this point. These Guidelines concern the treatment of
pneumonia that is covered by health insurance and the
treatment of pneumonia that is provided in beds in Japanese
hospitals that are designated for ‘‘general patients’’. If pneu-
monia that fulfills the definition of NHCAP at home or at a
nursing care facility, the patients themselves and their
families should consult with the medical institutions where
treatment is possible and then decide where the patient will
receive treatment.
In contrast to CAP and HAP, in which the patient popula-
tions exhibit relatively uniform features, it is difficult to
assess the severity of NHCAP by considering only the condi-
tion of the pneumonia itself. These Guidelines place primary
importance on the treatment that is required for a patient
when the attending physician decides on the treatment
category into which the patient falls, and have thus intro-
duced the concept of ‘‘patient treatment category’’.
Furthermore, the decision as to which treatment category
the patient is assigned to should be made by the attending
physician, who has the best knowledge of the individual
patient’s condition, background, family relationships, and so
forth. However, this strategy reveals a problem in regard to
medical care for the elderly.
There is still controversy as to whether to continue treat-
ment in cases in which it is impossible to achieve long-termimprovement. The decision as to which treatment category
the patient is assigned to is at the sole discretion of the
attending physician.
The four principles of biomedical ethics discussed by
Beauchamp and Childress are: (1) respect for autonomy, i.e.,
respecting the ability of individuals to make their own
decisions; (2) nonmaleficence, i.e., not inflicting harm on
others; (3) beneficence, i.e., preventing harm, offering benefit,
and balancing benefit against risk and cost; and (4) justice,
i.e., distributive justice for benefit, risk, and cost in regard to
medical practice related to a patient [5]. The ethical aspects
are especially important when considering medical care for
the elderly. The antibiotics recommended in these Guidelines
have been selected not only on the basis of the scientific
evidence but also the ethical aspects.
The above were our objectives and principles in preparing
these guidelines. We hope that these Guidelines will be widely
used by physicians and other medical practitioners in the
same way as the CAP, HAP, and respiratory infection guide-
lines published by Committee for the JRS Guidelines in
Management of Respiratory Infections have already been,
and that further progress will be made in the diagnosis and
treatment of pneumonia in Japan as a result.2. Definition of NHCAP
Summary HCAP is defined as pneumonia that overlaps both CAP and
HAP (Level I). Since most cases of HCAP in Japan are diagnosed in elderly
persons who are receiving nursing care, a separate diag-
nostic category, i.e., NHCAP, is needed (Minds recommen-
dation grade C1).
2.1. Clinical significance of HCAP in USA and other
countries
The disease concept HCAP was publicly described for the first
time in the HAP guidelines jointly published by the ATS and the
IDSA in 2005 (Fig. 2) [4]. In Japan, it is more appropriate to use
the term ‘‘NHCAP’’ instead of HCAP for the reasons stated below.
Internationally the term HCAP is generally used, and
initially the HCAP population was defined as a group of CAP
patients or HAP patients who had risk factors for involve-
ment by drug-resistant pathogens (Level I) [4].
However, many reports on HCAP, mainly from the United
States (U.S.) showed that the resistance of the causative
agents and outcomes (mortality rates) in HCAP were similar
to the resistance of the causative agents and outcomes
(mortality rates) in HAP (Supplementary material Fig. S1)
(Level IVa) [6,7] In other words, it was found that some of
the patients who had been admitted to a hospital with an
initial diagnosis of CAP were older and had a poorer outcome
than CAP patients, and the causative agents isolated from
most of them were drug-resistant pathogens (methicillin-
resistant Staphylococcus aureus (MRSA) and gram-negative
bacteria such as Pseudomonas aeruginosa), in addition to the
Fig. 2 – Definition of HCAP according to the ATS-IDSA 2005. Guidelines: risk factors for multidrug-resistant pathogens
causing HAP. Revised from Ref. [4].
Fig. 3 – Positioning of CAP, NHCAP, and HAP in Japan. No clear distinctions between CAP, NHCAP, and HAP can be made in
Japan. Would cases that have been counted as cases of CAP in Japan (e.g., cases in which the patient is convalescing at home
but has frequently been admitted to core hospitals) be counted as cases of HCAP in the U.S.?. Would cases counted as cases
of HAP in Japan (e.g., cases of repeated aspiration pneumonia at long-term care hospitals and not at acute care hospitals) be
counted as cases of HCAP in the U.S.?
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 0 3 – 1 2 6106pneumococci and Haemophilus influenzae that were the cau-
sative agents isolated from CAP patients.
HCAP patients are more likely to be diagnosed with CAP
than with HAP. It is more appropriate to define HCAP as
pneumonia that overlaps CAP and HAP and cannot be
classified as either CAP or HAP (Level I) [4,6].
Furthermore, treatment for HCAP may be similar to the
treatment for CAP or to the treatment for HAP, and it differs
from hospital to hospital.
2.2. NHCAP is Japanese version of HCAP: necessity of new
terminology for HCAP in Japan
There have been reports of data obtained from analyses of
HCAP in Japan as well (Level IVb) [8,9]. Since these reports
show that drug-resistant pathogens are a more common
cause of HCAP than of CAP, and also in view of prognoses andother assessments, the treatment of HCAP in Japan should be
based on the treatment of HAP. On the other hand, there is a
report that most HCAP in Japan is similar to CAP, pneumonia
with a poor outcome found largely in elderly patients, rather
than HAP, which is drug-resistant pneumonia caused by gram-
negative bacteria [10], and it is difficult to evaluate HCAP in
Japan in a standardized manner (Fig. 3) (Level IVb). Reports in
the U.S. and Europe have also pointed out that HCAP occurs in
heterogeneous populations [6,11,12], and in view of its original
definition, the true nature of HCAP can be described as a
mixture of cases of pneumonia with a poor outcome in elderly
patients that for the most part consists of aspiration pneumonia
and drug-resistant pneumonia resulting from an advanced-
medical-care environment (Fig. 4).
Furthermore, it has been pointed out that the differences in
the healthcare environment between communities or countries
are reflected in the incidence of HCAP and ratio of HCAP cases
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significantly from report to report (Fig. 5) (Level I) [4,8,13].
In particular, the definition of ‘‘hospital’’ in Japan is very
different from its definition in the U.S. This is largely because
there are many more extended-care facilities, including ‘‘nur-
sing homes’’ and ‘‘geriatric hospitals’’, in the U.S., and many
cases of pneumonia that have been diagnosed as HCAP in the
U.S. would have been diagnosed as HAP in Japan (Fig. 6) [3,14].
On the other hand, when NHCAP is viewed from a CAP
perspective, if a bedridden patient residing at home devel-
oped aspiration pneumonia or a dialysis patient with risk
factors for involvement by drug-resistant pathogens devel-
oped pneumonia and were transported to a nearby core
hospital, the patient would be treated for CAP in Japan [2]
whereas both would have been treated for HCAP in the U.S.
Because Japan has a unique nursing care insurance system and
healthcare and nursing care system, caution is required when
U.S. definitions are directly applied to the situation into Japan.
From this standpoint, the definitions of NHCAP are suggested
by the Committee for Preparation of Clinical Practice Guidelines for
Nursing- and Healthcare-associated Pneumonia (NHCAP) of the
Japanese Respiratory Society (Table 1). The definitions of NHCAP
reflect the fact that there are many cases of aspiration pneumo-
nia in the elderly in Japan on the background of the nursing care
insurance system, and the Committee considers it appropriate to
add the term ‘‘nursing care’’ and use the term ‘‘nursing- andFig. 5 – Proportions of CAP cases and
Fig. 4 – Pneumonia that does not completely meet the
definition of either CAP or HAP. There are two forms for
such pneumonia.healthcare-associated pneumonia (NHCAP)’’ to express HCAP
in Japan (see Section 1). Naturally, the definition of NHCAP
includes drug-resistant pneumonia that occurs during
advanced medical care, dialysis and immunosuppressant ther-
apy, and pneumonia caused by opportunistic pathogens.
Furthermore, these Guidelines emphasize that the selection of
treatment for NHCAP largely depends on the judgment of the
attending physician and should not be selected in a routine
manner. NHCAP can be viewed as ‘‘HCAP in Japan’’ or as ‘‘the
Nippon version of HCAP’’, and it is a highly original concept that
reflects the unique conditions within Japan.
2.3. Pathogenic mechanism
It is important to take special note of aspiration pneumonia
in regard to clinical practice related to NHCAP (see Section 8),
because many of the cases of NHCAP are cases of pneumonia
in the elderly (Table 2).
In addition to antibiotic therapy, preventive measures such
as vaccination (see Section 9) are particularly important
(Minds recommendation grade B).
We look forward to receiving many opinions and proposals
from readers that will further reflect the particular state of
healthcare in Japan.3. The concept of patient treatment category
SummaryHCInstead of classifying patients into categories based on the
severity of their illness, these Guidelines suggest classifying
patients into ‘‘patient treatment categories’’, which take
severity into account. Since the pathology, underlying diseases, and complica-
tions of NHCAP patients vary from case to case, it is
impossible to make a prognosis based on the severity of
the NHCAP and thus classifying patients with NHCAP
according to the severity of their illness is inappropriate. An NHCAP patient’s treatment category should be deter-
mined based on an assessment of all of the following:AP cases in Japan and abroad.
Fig. 6 – Categories of HAP, HCAP, and CAP by type of facility and type of patient in Japan: realities in the ‘‘Nursing Care
Insurance System’’.
Table 1 – Definition of NHCAP.
1. Pneumonia diagnosed in a resident of an extended care facility or
nursing home
2. Pneumonia diagnosed in a person who has been discharged from a
hospital within the preceding 90 days
3. Pneumonia diagnosed in an elderly or disabled person who is
receiving nursing care
4. Pneumonia diagnosed in a person who is receiving regular
endovascular treatment as an outpatient (dialysis, antibiotic
therapy, chemotherapy, immunosuppressant therapy)
Standards for nursing care.
Patients whose performance status is PS 3 (capable of only limited
self-care, confined to bed or a chair more than 50% of their waking
hours) or more.
Item 1 includes patients on psychiatric wards.
Table 2 – Main pathogenic mechanism of NHCAP.
1. Aspiration pneumonia
2. Bacterial pneumonia secondary to influenza
3. Drug-resistant pneumonia (such as MRSA pneumonia) secondary
to endovascular treatment, such as dialysis
4. Pneumonia caused by opportunistic microorganism during
treatment with an immunosuppressive agent or anticancer drug
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diseases, complications, nutritional status, psychological
and physical activity, and the state of support from other
persons responsible for the patient’s care (Minds recommen-
dation grade C1). The risk factors for involvement by drug-resistant patho-
gens are a history of antibiotic therapy within the preced-
ing 90 days or current tube feeding (Level IVa). Before determining the patient’s treatment category the
attending physician should thoroughly discuss the objec-
tives of treatment with the patient and the patient’s
family.
3.1. Suggestion of ‘‘patient treatment categories’’ for
NHCAP: why they are not ‘‘severity’’ categories
NHCAP occurs in the context of diverse pathology, underlying
diseases, and complications in a variety of environments, and
no two cases of NHCAP are the same (see Section 2). Thus,not only is it difficult to diagnose the severity of NHCAP in a
simple, standardized manner, but doing so would be inap-
propriate, because it is impossible to make a prognosis based
on the severity of NHCAP. After the topics of disease concept
and definition, and choice of antibiotics, this was the topic
that was most frequently discussed by the members of the
guideline preparation committee. Although the pathology of
CAP and pure HAP is similar, it is particularly evident in Japan
that NHCAP occurs in the form of various pathologies in
patients from a variety of residential environments who have
different underlying diseases and complications, and it is
difficult to stratify the cases according to severity or distin-
guish between different grades of severity. These Guidelines
propose giving priority to the treatment required by the
individual patient instead of severity when classifying them,
as described below (Fig. 7). Involvement by ‘‘high-risk’’ drug-
resistant pathogens, such as P. aeruginosa, extended-
spectrum b-lactamase (ESBL)-producing enteric bacteria,
and MRSA (see Section 4 for details), has been adopted as a
criterion for classifying patients according to treatment.
3.2. Basic concept of treatment categories
These Guidelines first classify NHCAP patients by initial treat-
ment from the standpoint of the types of treatment that are
required for NHCAP. If a physician examines a pneumonia
patient and diagnoses the pneumonia as NHCAP and the
Fig. 7 – Treatment category algorithm.
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intensive care in an intensive care unit (ICU) or mechanical
ventilation, or both, the patient is classified as ‘‘treatment
category D’’. Patients who are determined to require inpatient
treatment and have a risk of involvement by drug-resistant
pathogens are classified as ‘‘treatment category C’’. Patients
who are determined to require inpatient treatment and have
no risk factors for involvement by drug-resistant pathogens
are classified as ‘‘treatment category B’’. Patients for whom
outpatient treatment is appropriate are classified as ‘‘treat-
ment category A’’. These NHCAP patient’s treatment cate-
gories are determined not only on the basis of the severity of
the pneumonia itself but on the basis of the patient’s
environment, and they are not simply severity categories.
Furthermore involvement by drug-resistant pathogens must
always be considered during the treatment of NHCAP
patients.
3.3. Judging the need for hospitalization
The need for hospitalization is determined not only on the
basis of the severity of the pneumonia itself but on the basis
of the patient’s underlying diseases and complications, nutri-
tional status, psychological and physical activity, and support
by the patient’s family and other persons responsible for the
patient’s care, all of which are taken into consideration by the
attending physician when making the final decision in regard
to whether the patient requires hospitalization. While an
overall evaluation becomes necessary to determine the
‘‘patient’s treatment category’’, there are three sets of criteria
to help evaluate the severity of the pneumonia itself: (1) the
A-DROP classification (Supplementary material Table S1) for
evaluating the severity of pneumonia in the Japanese
Respiratory Society’s revised CAP guidelines [2]; (2) the I-
ROAD classification (Supplementary material Fig. S2) for
evaluating the severity of pneumonia in the JapaneseRespiratory Society’s revised HAP guidelines [3]; and (3) a
more detailed classification, the Pneumonia Severity Index
(PSI, Supplementary material Fig. S3) [15] cited in the IDSA’s
CAP guidelines [16–18]. The optimal set of criteria for each
patient’s condition should be selected from among these
three sets of criteria to assess the severity of the pneumonia,
and the patient’s underlying diseases and complications,
nutritional status, psychological and physical activity, and
social situation, such as the patient’s family situation, should
then be taken into consideration to determine the treatment
category and whether hospitalization is necessary.3.4. Risk factors for involvement by drug-resistant
pathogens
The patient’s treatment category is decided in order to
consider treatment options, which mainly consist of anti-
biotics. Involvement by drug-resistant pathogens is much
greater in NHCAP than in CAP, and depending on the patient,
involvement by drug-resistant pathogens may be greater
than in HAP. Thus, patients assigned to the treatment
category that requires hospitalization (but does not require
ICU care or mechanical ventilation) should be classified
separately based on the presence of risk factors for involve-
ment by drug-resistant pathogens so that drug selection can
be made based on this classification. Treatment category B
consists of patients who have been assessed as having no risk
factors for involvement by drug-resistant pathogens [8,19,20]
and includes patients who have not received antibiotics
within the preceding 90 days and who are not currently
receiving tube feeding, and if the patient is positive in regard
to either or both of these factors, the patient is classified into
treatment category C.
A history of antibiotic therapy refers to treatment with any of
a broad range of antibiotics (antipseudomonal penicillins, third-
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 0 3 – 1 2 6110or fourth-generation cephalosporins, carbapenems, quinolones)
for 2 or more days within the preceding 90 days [8] (Level IVb).
Patients with a history of MRSA isolation prior to the
preceding 90 days should be assumed to be at risk of MRSA
infection and are assigned to treatment category C.
3.5. Before the start of treatment
Because the pathology and background of NHCAP patients are
varied, the views and judgments of the attending physician play
a very large role in determining the treatment category and
timing of the start of treatment. Thus, it is important that the
attending physician hold thorough discussions with the patient’s
family and other persons responsible for the patient in regard to
the type of treatment that is most appropriate, including the
choice between outpatient and inpatient treatment, and attempt
to share the objectives of treatment with them.4. Pathogens and risk factors for involvement
by drug-resistant pathogens
Summary The most common causative agents isolated from Japanese
NHCAP patients are pneumococcus, Staphylococcus aureus
(including MRSA), Enterobacteriaceae, including Klebsiella and
Escherichia coli, and Pseudomonas aeruginosa (Level IVa). Reports indicate that drug-resistant pathogens, including
Pseudomonas aeruginosa, MRSA, and ESBL-producing Enter-
obacteriaceae, are the pathogens isolated in approximately
20% of NHCAP cases in Japan (Level IVa), but the data vary
with the facility and region (Level IVa). Risk factors for involvement by drug-resistant pathogens,
including, Pseudomonas aeruginosa, MRSA, and ESBL-
producing Enterobacteriaceae, include ‘‘history of antibiotic
therapy for 2 or more days in the preceding 90 days’’ or
‘‘current tube feeding’’ (Level IVa).Table 3 – Possible pathogens isolated from NHCAPWhen a patient does not have any risk factors for involve-
ment by drug-resistant pathogens, drug-resistant patho-
gens are less likely to be isolated from that patient (the
specificity and positive predictive value of being positive
for any of the risk factors is low, but the sensitivity and
negative predictive value are high) (Level IVa).patients.




 Gram-negative enteric bacteria (including Klebsiella and E. coli)
 Haemophilus influenzae
 Oral streptococci
 Atypical pathogens (particularly Chlamydophila)
When an NHCAP patient has a risk factor for involvement by drug-





 ESBL-producing enteric bacteriaBecause the occurrence of drug-resistant pathogens and
risk factors for involvement by them in NHCAP have been
found to differ from facility to facility, serious considera-
tion must be given to the actual data obtained at each
facility, such as the results of local surveillance (Level IVa).
4.1. Introduction
In contrast to the causative agents isolated from CAP
patients, the causative agents isolated from NHCAP patients
are likely to be drug-resistant pathogens (see Section 2).
However, NHCAP patients come from a variety of back-
grounds, and the composition and isolation rates of causative
agents differ with the facility and region. Thus, in routine
clinical practice, whenever possible it is desirable to considertherapeutic strategies in view of the actual data obtained at
each facility, such as the results from local surveillance and
antibiograms.
This section presents evidence related to pathogens and
risk factors for involvement by drug-resistant pathogens in
NHCAP patients. However, since no reports of studies in
which the diagnostic category NHCAP was used (see Section
2) had been published at the time these Guidelines were being
prepared, all descriptions in these Guidelines are based on
reports in regard to patients with the following types of
pneumonia to whom the various elements comprising the
definition of NHCAP apply: HCAP (according to the definition
used in the ATS-IDSA 2005 Guidelines); pneumonia in
patients at nursing facilities and long-term care facilities
(nursing home-acquired pneumonia, NHAP); pneumonia in
patients with poor activities of daily living (ADL); pneumonia
in dialysis patients; pneumonia in patients receiving che-
motherapy for a malignant disease; and pneumonia in
immunocompromised patients (final date of the literature
search: January 31, 2011). Furthermore, because the scarcity
of evidence on NHCAP is also a major issue from an interna-
tional perspective, this section will also mention the chal-
lenges that need to be met going forward.4.2. Pathogens in NHCAP
As shown in Table 3, the possible pathogens in NHCAP can be
divided into two groups according to whether the patient has
risk factors for drug-resistant pathogens.1) HCAP according to the definition used in the ATS-IDSA
2005 Guidelines.
The pathogens isolated from patients who meet the defini-
tion of HCAP in the ATS-IDSA 2005 Guidelines (Fig. 2) and
isolation rates differ with the region and country, and the
differences can be assumed to be attributable to the differ-
ences in healthcare systems [21] (Level VI).
There are five well-known epidemiological surveys of HCAP
[7,8,13,22,23] and the isolation rates of the main causative
agents isolated in these five surveys are shown in Table 4
[21]. In general, the isolation rates of pneumococci and
Table 4 – Pathogens (isolated) in 5 epidemiological studies.










(n¼85a) (n¼77a) (n¼65a) (n¼988a) (n¼431a)
Spain Japan South Korea U.S. U.S.
Causative agents (isolated) Facility: Single Single Single Multiple Multiple
Study design: Prospective Retrospective Retrospective Retrospective Retrospective
Gram-negative bacteria
Pseudomonas aeruginosa 2.6 10.4 13.8 25.3 25.5
Acinetobacter  2.1 0 2.6 
ESBL-producing enteric bacteria 0 1.3 10.8  
Klebsiella 0 13.0 20.0 7.6 6.5
E. coli 3.5 6.5 4.6 5.2 4.2
Haemophilus influenzae 17.6 5.2 6.2 5.8 4.2
Other gram-negative bacteria  10.4 6.2 13.0 19.0
Gram-positive bacteria
Pneumococci 41.2 24.7 38.5 5.5 10.4
Staphylococcus aureus 3.5 18.2 20.0 46.7 44.5
MRSA 1.2 6.5 7.7 26.5 30.6
Streptococci other than pneumococcus  7.1 1.5 7.8 
Other gram-positive bacteria  2.8 0 7.7 
Values shown are percentages (%).
Revised from: Shindo Y, Hasegawa Y. Applied technologies in pulmonary medicine. Basel: Karger; 2011. p. 172–7.
a Cases in which the pathogens were unknown have been excluded.
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isolated from CAP patients, and the isolation rates of MRSA,
Pseudomonas aeruginosa, and gram-negative bacteria, which
are known to be frequently isolated from HAP patients,
differ from country to country [4,8,17,24] (Level IVa).
The results of epidemiologic studies conducted in Japan
have shown that drug-resistant pathogens, including
Pseudomonas aeruginosa, MRSA, and ESBL-producing Enter-
obacteriaceae, which may not be targeted for CAP therapy,
have been isolated in approximately 20% of the cases in
which the pathogen was known [8,9] (Level IVb). It is
noteworthy that pneumococcus is the pathogen most
frequently isolated in HCAP in Japan, the same as in CAP,
whereas drug-resistant pathogens, including Pseudomonas
aeruginosa, MRSA, and ESBL-producing Enterobacteriaceae,
are isolated more frequently in HCAP than in CAP, but less
frequently in HAP [8,24] (Level IVa).2) Pneumonia in patients at nursing facilities and long-term
care facilities (NHAP)
Three reports on NHAP cases from Japan indicate that the
pathogens listed in Table 3, including pneumococcus,
Staphylococcus aureus, MRSA, Pseudomonas aeruginosa, and
E. coli, are the pathogens that are most often isolated in
NHAP, the same as in HCAP [10,25,26] (Level IVa). However,
there were variations in their isolation rates according to
the facility, and the ranges of the isolation rates of three of
them were: pneumococcus, 2–33%; Staphylococcus aureus,
1–8%; and MRSA, 1–23%. Furthermore, since the data in
these reports were obtained from inpatients, they do not
include data on patients treated at nursing care facilities.
Thus, the overall situation in regard to pneumonia
patients at nursing care facilities remains unclear.
Reports from other countries also indicate that the patho-
gens listed in Table 3 are often isolated in NHAP, the sameas in Japan, and there are also differences between the
isolation rates of drug-resistant pathogens according to
facility and region [19,27,28] (Level IVa).
There have also been reports of a Chlamydophila pneumoniae
isolation rate of 34.7% and a Mycoplasma pneumoniae isola-
tion rate of 9.3% in Japan, suggesting that Chlamydophila is
particularly targeted for the treatment of NHAP patients,
since its isolation rate is about the same as in CAP [10]
(Level IVa).3) Pneumonia in patients with poor ADL
There are three reports from Japan related to patients who
meet the third requirement in the definition of NHCAP
(NHCAP patients with poor ADL): ‘‘Elderly or disabled and
requiring nursing care’’, and all three reports state that the
pathogens listed in Table 3, including pneumococci and
other streptococci, MRSA, Klebsiella, Pseudomonas aeruginosa,
and methicillin-susceptible Staphylococcus aureus (MSSA),
are the pathogens that are most often isolated in patients
with poor ADL, the same as in HCAP and NHAP [29–31]
(Level IVa). In addition, there is a report of a study in which
atypical pathogens (Chlamydophila and Mycoplasma pneumo-
niae) were isolated from a high proportion of patients with
poor ADL, 44.7% [30] (Level IVa).
On the other hand, studies conducted on pneumonia in
elderly patients abroad that included patients with poor
ADL have reported that pneumococcus, Haemophilus influenzae,
and gram-negative bacteria were the most frequently isolated
pathogens [32,33,35]. Isolation of Legionella pneumophila has
also been reported [32] (Level IVa).4) Pneumonia in dialysis patients
It is well known that drug-resistant pathogens such as
MRSA are more frequently isolated as pathogens from
patients with healthcare-related bloodstream infections,
including dialysis patients, than from patients with
Table 5 – Risk factors for involvement by drug-resistant
pathogensa in NHCAP.
 History of antibiotic therapy for 2 or more days in the preceding
90 days
 Current tube feeding
a Drug-resistant pathogens include Pseudomonas aeruginosa, MRSA,
Acinetobacter, ESBL-producing enteric bacteria, and Stenotropho-
monas maltophilia.
The risk of MRSA should be taken into account whenever there is
past history of MRSA isolation.
When attempting to predict the isolation of drug-resistant patho-
gens based on the presence of these risk factors, it should be
borne in mind that their sensitivity and negative predictive value
are high, but their specificity and positive predictive value are low.
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IVa). However, there have been few reports on causative
agents isolated from pneumonia patients on dialysis.
A report on hospitalized dialysis patients abroad showed
that the most frequently causative agents were, in descend-
ing order, gram-negative bacteria, Pseudomonas aeruginosa,
and MRSA, and the pneumococcus isolation rate was 6%
[36] (Level IVb). There have been studies on nosocomial
pneumonia in dialysis patients in Japan that reported high
isolation rates for Pseudomonas aeruginosa, MRSA, and gram-
negative Enterobacteriaceae, although many cases appear not
to have met the definition of NHCAP, because they included
HAP patients [37] (Level IVb).
In prospective studies conducted abroad on the risks of
infection by MRSA and multidrug-resistant gram-negative
bacteria in pneumonia diagnosed in dialysis patients,
15–28% of outpatients were reported to be carriers of MRSA
or multidrug-resistant gram-negative bacteria [38,39]. How-
ever, the isolation rate of multidrug-resistant bacteria from
hemodialysis patients in Japan is unknown.5) Pneumonia in patients receiving chemotherapy for a
malignant disease
Chemotherapy for malignant diseases is known to lower
immunocompetence and increase the risk of respiratory
infection. Many different types of pathogens may be
involved in respiratory infections. Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, and Nocardia are the types of
bacteria that are most commonly isolated in patients who
develop pneumonia while on chemotherapy for a malig-
nant disease, and viruses, including RS virus, parain-
fluenza virus, influenza virus type A and type B,
cytomegalovirus, fungi, including Aspergillus, Fusarium,
and Mucor, and Pneumocystis jirovecii are also said to
sometimes be involved [40] (Level IVa). However, because
no reports have separated the data obtained from inpa-
tients and outpatients, evidence on patient groups that
meet the definition of NHCAP is scarce.6) Pneumonia in immunocompromised patients
The list of possible causative agents of pneumonia in
immunocompromised patients should include bacteria,
acid-fast bacilli, fungi, Pneumocystis jirovecii, and viruses
[41] (Level IVa). When attempting to identify causative
agents at the time of diagnosis, it should be noted
that their spectrum is affected by whether the type of
immunodeficiency is a decrease in neutrophils, humoral
immunodeficiency, or cellular immunodeficiency [3].
A comprehensive determination should be made by taking
into account the clinical signs and course, information
obtained from samples collected from respiratory organs,
and the results of serodiagnosis, diagnostic imaging, e.g.,
by HRCT, urinary antigen tests, and other diagnostic
studies [3,42] (Level IVa).
4.3. Risk factors for involvement by drug-resistant
pathogens in NHCAP
Risk factors for involvement by drug-resistant pathogens in
NHCAP include ‘‘history of antibiotic therapy for 2 or moredays in the preceding 90 days’’ or ‘‘current tube feeding’’
(Table 5) [8,12,19,20] (Level IVa).
However, risk factors for involvement by drug-resistant
pathogens in NHCAP may vary with the facility. When
attempting to predict the isolation of drug-resistant patho-
gens based on the presence of these risk factors, it must be
borne in mind that their specificity and positive predictive
value are low, but their sensitivity and negative predictive
value are high (Level IVa).1) Definition of drug-resistant pathogens
In NHCAP, ‘‘drug-resistant pathogens’’ include Pseudomonas
aeruginosa, Acinetobacter, ESBL-producing Enterobacteriaceae,
MRSA, and S. maltophilia [4,7,8,43–45].2) Risk factors for involvement by drug-resistant pathogens
Two of the studies related to NHCAP, one in Japan and the
other abroad, attempted to identify risk factors for invol-
vement by drug-resistant pathogens [8].
In the study conducted in Japan, ‘‘history of treatment
with a broad-spectrum antibiotic for 2 or more days in the
preceding 90 days (anti-pseudomonal penicillins, third or
fourth- generation cephalosporins, carbapenems, fluoro-
quinolone antibacterial agents)’’ and ‘‘current tube feed-
ing’’ were shown to be significant risk factors for
involvement by drug-resistant pathogens, and the odds
ratio was 3.1 and 2.5, respectively [8] (Level IVb).
‘‘History of antibiotic therapy for 2 or more days in the
preceding 6 months’’ and ‘‘ADL scores [48] above 12.5
points’’ have been shown to be significant risk factors in
the study of severe NHAP conducted abroad [19]. Further-
more, a combination of these two risk factors predicted
isolation rates of drug-resistant pathogens (Pseudomonas
aeruginosa and MRSA) with 100% sensitivity and 69.4%
specificity.
In other words, they suggested that no drug-resistant
pathogens would be isolated unless both of these risk
factors were present (Level IVa).
There is a report indicating that current tube feeding is an
independent risk factor for Pseudomonas aeruginosa infection
(odds ratio: 13.9) [20] (Level IVa), and current tube feeding is
viewed as a possible alternative to poor ADL as an indicator of
the presence of drug-resistant pathogens [12] (Level IV).
The 2005 ATS-IDSA Guidelines mention risk factors for
multidrug-resistant pathogens (Fig. 2) [4]. A report that praises
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Guidelines points to their high sensitivity and high negative
predictive (96% and 97%, respectively) and their low specifi-
city and positive predictive value (22% and 17%, respectively)
[46] (Level IVa). Therefore, it suggests that their poor specifi-
city for predicting isolation of drug-resistant pathogens is a
problem, the same as in the study mentioned above [19].3) The issues of drug-resistant pathogens—inappropriate initial
antibiotic therapy, relationship to the prognosis
NHCAP patients receive inappropriate initial antibiotic
therapy (therapies in which drugs with low drug sensitivity
are selected as initial antibiotic regimens) more often than
CAP patients do, and receiving inappropriate initial anti-
biotic therapy adversely affects their prognosis. Thus, the
initial antibiotic therapy for NHCAP patients should be
selected more carefully than for CAP patients, by taking
into account drug-resistant pathogens that are associated
with inappropriate initial antibiotic therapy [4,6,8,11,13,17,
21–23,49–55](Level IVa).
In a study conducted abroad Micek et al. reported finding
that the mortality risk of inpatients was 2.2 times higher
when inappropriate initial antibiotic therapy had been
prescribed. The report said that inappropriate antibiotic
therapy was prescribed for a higher proportion of HCAP
patients than for CAP patients (30.9% vs. 13.6%, p¼0.002),
and that there was a significant correlation between the
inappropriate initial antibiotic therapy and involvement by
drug-resistant pathogens [23] (Level IVb).
A study conducted in Japan reported finding that inap-
propriate initial antibiotic therapy was prescribed for a
higher percentage of HCAP patients than for CAP patients
(20.8% vs. 9.7%, p¼0.038), and that when drug-resistant
pathogens were isolated from HCAP patients the odds ratio
of inappropriate initial antibiotic therapy was 14.0 (95% CI:
4.5–43.6) [8] (Level IVb).
A study on NHAP conducted in Spain reported that when
gram-negative bacteria or MRSA that had low drug sensi-
tivity were isolated, the odds ratio of 1-month mortality
was 16.4, and that there was a significant correlation
between the drug-resistant pathogens and mortality [28]
(Level IVa).4) Relationship between isolation of drug-resistant patho-
gens and severity
A report on HCAP in Japan showed that there was little
correlation between the severity of HCAP evaluated on the
basis of the A-DROP classification [56] and isolation of drug-
resistant pathogens [8] (Level IVb). However, there are
several studies conducted abroad whose results suggest a
correlation between the severity of HCAP and isolation of
drug-resistant pathogens [19,52] (Level IVa) and a report
that proposed initial antibiotic treatment strategies that
take severity levels into account [11] (Level VI), and there is
no consensus in regard to whether a correlation exists
between the severity of HCAP and isolation of drug-
resistant pathogens. The proposal of an initial antibiotic
treatment strategy that takes severity levels into account is
based on the results of studies which suggest that treat-
ment with multiple broad-spectrum antibiotics, as recom-
mended in the ATS-IDSA 2005 Guidelines, is unnecessary in
patients whose condition is not severe [47,57,58] (Level II).4.4. Discussion and future challengesAs shown in Table 4, there are differences from country to
country in the causative agents isolated from NHCAP patients,
and in Japan there are even differences between facilities. Thus,
when considering initial antibiotic therapy, it is desirable to
refer to as much data, such as local surveillance data and
antibiograms obtained at each facility, as possible.
Drug-resistant pathogens such as gram-negative Enterobacter-
iaceae that have low drug sensitivity, including Pseudomonas
aeruginosa, MRSA, and ESBL-producing Enterobacteriaceae, are
often isolated from patients who meet the definition of NHCAP
both in Japan and abroad. Pneumococcus, which is often
isolated from CAP patients, is also isolated from NHCAP
patients. Because there are also cases in which atypical patho-
gens (particularly Chlamydophila) are assumed to be involved,
treatment targeting them may be necessary. However, since
there is insufficient evidence to support our predictions, it will
be necessary to provide evidence through prospective immu-
nology studies and clinical tests.
NHCAP patients are extremely diverse. There is little
evidence as to the answers to the questions: ‘‘Are multiple
broad-spectrum antibiotic regimens actually necessary in
therapies targeting drug-resistant pathogens?’’, ‘‘What are
the risk factors for drug-resistant pathogens?’’ and
‘‘What are their evaluation methods with high sensitivity
and high specificity?’’ At present, the following issues need to
be classified [21,56]:(1) Essential risk factors for drug-resistant pathogens(2) Whether weighting (stratification, scoring) of each of the
risk factors for drug-resistant pathogens is necessary(3) Whether there is a relationship between drug-resistant
pathogens and severity (whether severity is a risk factor
for drug-resistant pathogens or not)
The aging of Japanese society is predicted to accelerate, and
the number of NHCAP patients as a proportion of all pneumo-
nia patients is expected to continue to increase. Treatment
strategies for NHCAP that are effective and efficient need to be
discussed as crucial challenges, and high quality research and
investigations must be conducted to elucidate the items above.5. Diagnostic testing
Summary Expectorated sputum culture results do not directly mean
the causative agents of pneumonia patients. Identification of the bacterial pathogens in pneumonia
patients requires quantitative culture of sputum speci-
mens that have been obtained from the lower respiratory
tract by invasive methods in order to avoid contamination
of oral bacteria (Level IVa). Drug-resistant pathogens are often detected in the spu-
tum of NHCAP patients, but they are not always the
causative agent (Level IVb). Expectorated sputum should not be used for cultures of
anaerobic bacteria (Minds recommendation grade D).
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lected by tracheal suction might be reliable methods of
identifying the causative agents in patients who have been
intubated for management of mechanical ventilation
(Level IVa).
5.1. Limitations of bacteriologic testing in NHCAP
Expectorated sputum is inadequate as a specimen for identi-
fying the causative agents of pneumonia, because it is
impossible to know whether an expectorated sputum speci-
men originated at the site of the pneumonia lesion and
because sputum becomes contaminated by indigenous oral
bacteria and colonized bacteria in the respiratory tract as it is
expectored, which makes it impossible to determine whether
the bacteria that grow out in cultures are the pathogens that
are causing the pneumonia, colonized bacteria in the respira-
tory tract, or indigenous oral bacteria.
It is reported to be possible to identify the causative agent
in pneumonia patients by quantitatively culturing sputum
specimens collected from the site of the infection by bronch-
oalveolar lavage (BAL), by a protected specimen brush (PSB),
or, in patients who have been intubated, by tracheal aspira-
tion (Level I) [4].
Since many NHCAP patients in Japan are elderly or bed-
ridden and even collecting expectorated sputum specimens
may be difficult, with the exception of a small number of
facilities, invasive diagnostic procedures are rarely carried
out promptly in Japan. Thus it is difficult to diagnose NHCAP
based on bacteriological examinations. The results of bacter-
iological examinations should be used as one of the evi-
dences for making decisions in regard to diagnosis and
treatment, and empiric therapy should take priority in regard
to antibiotic therapy (Minds recommendation grade C1).
5.2. Interpretation of causative agent in NHCAP
Studies conducted on NHCAP to date have reported that
multidrug-resistant (MDR) pathogens are often isolated from
NHCAP patients and that the rate of isolation of drug-resistant
pathogens such as Pseudomonas aeruginosa and MRSA is
significantly higher than in CAP (Level IVa) [7–9,13,22,23,48].
However, these studies on the causative agents isolated in
NHCAP report the isolation rates of pathogens in bacteriolo-
gical tests and do not specify the method used to collect the
specimens, but most of them clearly use expectorated sputum
as the specimens. Thus, it is uncertain whether the isolated
bacteria are the actual causative agents [12].
5.3. Bacteriologic diagnostic testing methods
If expectorated sputum has been obtained before any anti-
biotics have been administered, bacteriological tests should
be performed on the sputum.
Gram stain and cultures should be performed using expec-
torated sputum. Only aerobic culture is desirable. Because
expectorated sputum is contaminated by indigenous oral
bacteria, it is unsuitable for culturing anaerobic bacteria.
Since urinary antigen tests are a simple method of detecting
pneumococci and Legionella pneumophila, they should beperformed whenever possible, and now antigen tests for
expectorated sputum itself have been approved for
pneumococcus.
Culture tests are not standard procedure for identifying the
pathogens in atypical pneumonia or viral pneumonia.
Usually when a diagnosis of atypical pneumonia is made,
titers of IgG antibodies against Mycoplasma and Chlamydia in
paired sera and IgM antibody titers in the initial phase of the
infection are measured. A rapid diagnostic test for influenza
is one of the limited numbers of diagnostic methods that are
available for viral pneumonia. Except influenza, a definitive
diagnosis of viral pneumonia is usually made on the basis of
antibody titers. Although PCR diagnosis is possible at some
facilities, it is not generally used.
There is a report that when quantitative cultures of endo-
tracheal aspirated sputum from patients with severe NHCAP
who had been intubated for mechanical ventilation yielded a
number of organisms greater than 106 CFU/mL, it was the
causative agent in a high percentage of the cases (90%
sensitivity, 77% specificity) (Level IVa) [59]. On the other hand,
there are also reports stating that for ventilator-associated
pneumonia (VAP) patients, when the pathogen is not isolated
by tracheal aspiration, the specificity that the pathogen is not
the causative agent is 94% (Level IVa) [60].
When tuberculosis cannot be ruled out by chest X-rays,
etc., specimens should always be collected from respiratory
tract to stain for acid-fast bacteria and culture for mycobac-
teria. A PCR test of specimens collected from respiratory tract
and a quantiFERONs test are also effective methods of
diagnosing tuberculosis.
Please refer to other documents in the literature in regard
to the diagnosis of fungal pneumonia or pneumocystis
pneumonia.
5.4. Routine testing methods for the diagnosis of
pneumonia
If a shadow is detected on a chest X-ray, and one or more of
the following four findings is present: leukocytosis, fever,
purulent sputum, high C-reactive protein (CRP) level, a
diagnosis of pneumonia should be made and bacteriological
tests should be performed.
When blood culture is possible, two or more sets of speci-
mens should be taken for the bacteriological tests. If expec-
torated sputum specimens are collected, smear microscopy
should be performed and, if it is evaluated to be of good
quality, the microbiological result of culture is somewhat
reliable. Urinary antigen tests for pneumococci should be
performed whenever possible, and the Legionella urinary
antigen test should be performed in severe cases or cases
that are becoming more severe.6. Antibiotic selection
Summary Treatment strategies should be decided from the stand-
point of ‘‘respect for autonomy (of the patient)’’ by the
attending physician, who has the best understanding of
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lives, and who will respect the wishes of the patient and
the patient’s family (Minds recommendation grade C1). Because there is no risk of involvement by drug-resistant
pathogens in patients in treatment category A or treat-
ment category B, a narrow-spectrum antibiotic should be
selected in the same manner as for the treatment of CAP
pneumonia (Minds recommendation grade C1). Because they are at risk for involvement by drug-resistant
pathogens, patients in treatment category C should be
treated with one of the broad-spectrum antibiotics for
which a low incidence of adverse reactions has been
reported (Minds recommendation grade C1). A powerful broad-spectrum antibiotic, including an anti-
biotic for the treatment of drug-resistant pathogens and
rare pathogens such as Legionella, should be selected for
the treatment of patients in treatment category D, because
of their poor prognosis (Minds recommendation grade C1).
6.1. Appropriate and inappropriate antibiotic therapy
There have been reports of patients who received inappropriate
treatment having a significantly poorer outcome than patients
who received appropriate treatment [7–9,13,22,23,48,50] (Level II).
Moreover, even when the treatment of patients who received
inappropriate treatment was changed to appropriate treatment
with a broad-spectrum antibiotic, their outcomes failed to
improve (Level IVa) [48], thereby demonstrating the importance
of appropriate initial antibiotic selection. However, since these
data include pathogens isolated by culturing expectorated spu-
tum, it is uncertain whether the bacteria isolated were the actual
causative agents. On the other hand, it is unclear whether
selecting the most appropriate antibiotic for the patients from
which drug-resistant pathogens had been isolated would have
improved their outcome (Level IVa) [61,62].
Drug-resistant pathogens are involved in a high proportion of
NHCAP patients. However, since the pathogens isolated are not
necessarily the causative agent, selecting an antibiotic targeting
that pathogen alone may lead to overtreatment (Level I) [11,12].
The approach to the treatment of patients in whom drug-
resistant pathogens may be involved that is recommended in
the ATS/IDSA guidelines [4] (Level I) is to administer a broad-
spectrum antibiotic immediately and allow streamlining or
de-escalation whenever possible 48–72 h later, when the
results of the cultures to identify the causative agent are
available. The risk factors for involvement by drug-resistant
pathogens in the ATS/IDSA guidelines have become the basis
for the definitions for HCAP.
However, it was reported that the outcome of ICU patients
in whom involvement by drug-resistant pathogens was
suspected and who were treated with recommended drugs
was significantly worse than that of those who were treated
with non-recommended drugs, whether thorough bacterio-
logical tests had been performed to identify the causative
agent or not [63] (Level II). That finding suggested that
appropriate treatment with an antibiotic targeting the cau-
sative agent does not necessarily improve the outcome of
patients with involvement by drug-resistant pathogens, andpatients’ baseline condition or adverse reactions of the
antibacterial drugs may affect their outcome.
6.2. Basis for antibiotic selection and key points
In Japan, there are few opportunities to use invasive broncho-
scopic techniques to collect sputum from NHCAP patients, and
there are few facilities where quantitative sputum cultures are
performed. It is extremely difficult to identify causative agents
based on information obtained from the results of bacteriologic
screening of sputum specimens, and, as stated in Section 5, it is
impossible to determine whether anaerobic bacteria and indi-
genous oral bacteria, which are frequently found in the elderly,
are involved in aspiration pneumonia.
Thus, this Guideline recommends empiric treatment based
on the data in regard to pathogens isolated in the past when
selecting antibiotics, and that antibiotic streamlining and de-
escalation be considered based on the results of attempts to
isolate causative agents from blood or good quality of expec-
torated sputum specimens (Minds recommendation grade
C1). However, from the standpoint of nonmaleficence toward
patients who have complications and are in poor general
condition or are in the terminal phase of their illness, it is
recommended that adverse reactions be taken into account
when selecting antibiotics.
6.3. Basic concepts in regard to antibiotic selection
NHCAP patients have a poorer outcome than CAP patients,
and are more likely to have involvement by drug-resistant
pathogens (Level I) [7–9,13,22,23,48,50]. Therefore, it is recom-
mended that the antibiotic with activity against the possible
causative agent be selected for initial treatment. The condi-
tion that should be considered first in NHCAP patients is
aspiration pneumonia (Level IVa) [13,64,65]. The proportion of
NHCAP patients with involvement by drug-resistant patho-
gens is higher among those who have received recent anti-
biotic therapy and those who have a history of hospitalization
(within 3 months) (Level IVa). Thus, it is necessary to
empirically select antibiotics for initial treatment that target
these conditions and pathogens.
Needless to say, targeted therapy is ideal when the causa-
tive agent is known, but it is impossible to identify the
causative agent of pneumonia by examinations of expecto-
rated sputum alone.
Thus, from the standpoint of ‘‘respect for autonomy’’, these
guidelines entrust the final decision regarding the assign-
ment of patients to a treatment category to the attending
physician, who can investigate the way of life and family
history of the patient and the patient’s family.
A narrow-spectrum antibiotic that targets, pneumococcus,
Haemophilus influenzae, Klebsiella, Staphylococcus aureus, and
anaerobic bacteria, or combination therapy is recommended
for the treatment of patients assigned to treatment category
A and treatment category B, who have no risk factors for
involvement by drug-resistant pathogens (Minds recommen-
dation grade C1).
Out of respect for the principle of nonmaleficence it is
recommended that broad-spectrum antibiotics with a low
incidence of adverse reactions be selected for the treatment
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 0 3 – 1 2 6116of the patients in treatment category C, who have risk factors
for involvement by drug-resistant pathogens (Minds recom-
mendation grade C1).
Out of respect for the principle of beneficence, selection of
powerful broad-spectrum antibiotics, including antibiotics
for drug-resistant pathogens and rare pathogens such as
Legionella, is recommended for the treatment of the patients
in treatment category D, who have been ‘‘determined to
require intensive care, such as mechanical ventilation’’
(Minds recommendation grade C1).
These recommendations have been referred to as guide-
lines, and it is necessary for the attending physician to hold
thorough discussions with the patient, the patient’s family,
and the healthcare team in order to decide on treatment





CPOutpatient treatment: patients with no risk factors for invol-
vement by drug-resistant pathogens (treatment category A)
The main targets of the outpatient treatment of patients with
no risk factors for involvement by drug-resistant pathogens. 8 – Recommendations of initial empiric antibiotic therapy. AM
M: clarithromycin; AZM: azithromycin; GRNX: garenoxacin; MF
T/ABPC: sulbactam/ampicillin; PAPM/BP: panipenem/betamipro
astatin; MEPM: menopenem; DRPM: doripenem; CFPM: cefepim;
FX: ciprofloxacin; PZFX: pazufloxacin; VCM: vancomycin; TEIC :(Treatment category A) are pneumococcus, Haemophilus
influenzae, Staphylococcus aureus, Klebsiella, and Chlamydophila
pneumoniae (Level IVa, Minds recommendation grade C1).
The antibiotics recommended for patients in treatment
category A are b-lactamase inhibitor combined with penicil-
lins (SBT/ABPC, CVA/AMPC), respiratory quinolones (GRNX,
MFLX, LVFX), or macrolide antibiotics (CAM, CVA/AZM).
Because b-lactamase inhibitor combined with penicillins
are not effective against atypical pneumonia pathogens such
as Chlamydophila pneumoniae, they should be used concur-
rently with a macrolide. Since CTRX has a long half-life and
high blood concentrations can be maintained with a single
daily dose, it is suitable for outpatient therapy. CTRX is not
effective against atypical pneumonia pathogens, so it should
be used in combination with a macrolide. Since the activity
of CTRX against anaerobic bacteria is insufficient, concomi-
tant treatment with one of the macrolides, which have some
degree of effectiveness against oral anaerobic bacteria, is
thought to increase activity against anaerobic bacteria [66].
In addition, single-dose AZM-SR is currently available on the
market and good compliance with AZM-SR therapy has been
demonstrated. Because of its weak activity against anaerobic
bacteria, selection of LVFX should be avoided if aspiration
pneumonia is suspected.PC/CVA: amoxicillin/clavulanic acid; SBTPC: sultamicillin;
LX: moxifloxacin; LVFX: levofloxacin; CTRX: ceftriaxone;
n; TAZ/PIPC: tazobactam/piperacillin; IPM/CS: imipenem/
CPR: cefpirome; MTZ: metronidazole; CLDM: clindamycin;
teicoplanin; LZD: linezolid.
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drug-resistant pathogens are present (treatment category B)
The main targets of inpatient treatment of patients with no
risk factors for involvement by drug-resistant pathogens
(treatment category B) are pneumococcus, Haemophilus
influenzae, Staphylococcus aureus, Klebsiella pneumoniae, and
Chlamydophila pneumoniae (Level IVa) [8,9].
The recommended injectable antibiotics are the b-lacta-
mase inhibitor combined with penicillin SBT/ABPC, cepha-
losporin antibiotics, such as CTRX, the carbapenem
antibiotic PAPM/BP, and the respiratory quinolone LVFX.
If a patient from a nursing facility for the elderly is
admitted to a hospital for pneumonia and there is no risk
factor of involvement by drug-resistant pathogens, the
causative agents of common respiratory infections or
aspiration should be suspected, and the antibiotics should
be selected accordingly.
Because CTRX is mainly metabolized in the liver, it can be
used to treat patients with impaired renal function. How-
ever, CTRX has weak activity against anaerobic bacteria.
PAPM/BP is one of carbapenem antibiotics, and although its
antibacterial activity against Pseudomonas aeruginosa is
weak, it is effective against pneumococcus and anaerobic
bacteria. SBT/ABPC is useful against anaerobic bacteria
and pneumococcus, Staphylococcus aureus, and Moraxella.
b-lactamase-negative ABPC resistant (BLNAR) Haemophilus
influenzae have recently increased, and SBT/ABPC is inef-
fective against Haemophilus influenzae (PIPC is effective).
The above-mentioned b-lactam antibiotics are ineffective
against Chlamydophila pneumoniae. LVFX injections are effec-
tive against a broad spectrum of causative agents in
respiratory infections, from Chlamydophila pneumoniae and
Haemophilus influenzae to pneumococcus, but LVFX injec-
tions have little activity against anaerobic bacteria. Thus,
CTRX and LVFX are inappropriate choices when aspiration
pneumonia is suspected.3) Inpatient treatment: when a risk factor for involvement by
drug-resistant pathogens are present (treatment category C)
In addition to the causative respiratory pathogens men-
tioned above, the targeted microorganisms for inpatient
treatment of patients who have risk factors for involvement
by drug-resistant pathogens include, Pseudomonas aeruginosa,
MRSA, and Acinetobacter (Level IVa) [8,9,65,66].
The antibiotics recommended for inpatient treatment of
patients who have a risk factor for involvement by drug-
resistant pathogens (treatment category C) are TAZ/PIPC,
fourth generation cephalosporins, carbapenems, and new
quinolones (CPFX, PZFX) which have activity against Pseudo-
monas aeruginosa. Because fourth-generation cephalosporin
and new quinolone antibiotics have weak activity against
anaerobic bacteria, they should be used concomitantly with
MTZ, CLDM, or SBT/ABPC. If there is a risk of involvement
by MRSA, for example, because of a history of hospitalization,
VCM, TEIC, or LZD should be selected. ABK is also effective.
Since none of the above antibiotics except the quinolones
have any activity against atypical pneumonia pathogens such
as Chlamydophila pneumoniae, a quinolone or a macrolide is
recommended for the treatment of patients suspected of
having atypical pneumonia that occurs in epidemic out-
breaks. TAZ/PIPIC has been reported to exhibit activity thatis equivalent to the activity of IPM/CS in NHAP patients [29].4) Severe cases requiring intensive care (treatment category D)
In combination with antibacterial drugs recommended for
the treatment of hospitalized patients who may have drug-
resistant pathogens, injections of new quinolones such as
CPFX or PZFX, or the macrolide AZM are recommended for
the severe cases requiring intensive care as treatment for
infection by Legionella and atypical pathogens, which are
rarely isolated but may cause severe illness (Minds recom-
mendation grade C1).5) Modification of antibiotic recommendations according to
the rates of isolation of drug-resistant pathogens
The effectiveness of antibiotics against community-
acquired infections varies with the rates of isolation of
drug-resistant pathogens. ESBL-producing enteric bacteria
Klebsiella currently require particular attention. Klebsiella
are a key group of bacteria that are isolated at a higher
rate from NHCAP patients than from CAP patients. With
the exception of carbapenems, b-lactam antibiotics are
ineffective against ESBL-producing Klebsiella. While the
isolation rates of ESBL-producing Klebsiella have ranged
from about 2% to 5% in a nationwide surveillance [67],
since the rates were as high as 10% to 20% in some
regions, penicillins and cephalosporins should be removed
from the list of selections for empiric therapy (Level IVb,
Minds recommendation grade C1). The clinical effects of
TAZ/PIPC on ESBL-producing Klebsiella have not been
confirmed.
6.5. Antibiotic dosage strategies1) Antibiotic dosage and duration of therapy
The doses of antibiotics prescribed in Japan tend to be low
from the view point of the PK-PD theory. Thus, for HAP in
which there is a high isolation rate of drug-resistant patho-
gens, treatment with high doses of antibiotics has been
recommended as initial treatment, when drug sensitivity is
unknown [68]. Since elderly patients comprise the majority
of NHCAP patients, the antibiotic dosage should be adjusted
as indicated in Section 7, ‘‘Antibiotic therapy and general
management of the elderly pneumonia patients’’.
Since there is no clear evidence concerning the duration of
antibiotic therapy for NHCAP, the most commonly prescribed
7- to 10-day regimen would appear to be most appropriate
(Level IVb, Minds recommendation grade B) [67]. If the
duration of treatment is prolonged beyond 7 to 10 days, an
antibiotic with the same spectrum of activity or antibiotic de-
escalation should be selected. Fever, the serum CRP level, and
the leukocyte count are often used as indicators of the
efficacy of antibiotic therapy. However aspiration can recur
during effective antibiotic therapy for aspiration pneumonia,
and it is necessary to determine whether the antibiotic is
ineffective or aspiration has recurred.2) Changes and modification of antibiotics
When a broad-spectrum antibiotic has been selected for initial
treatment and the causative agent has subsequently been
identified, it is desirable to make changes based on the
causative agent that has been identified. However, since
pathogens isolated from expectorated sputum are not
Fig. 9 – Streamlining and changes in antibiotics.
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that therapy targeting the pathogen isolated is correct.
The antibiotic regimen should be modified based on not
only the results of bacteriological tests but a comprehensive
assessment of the overall clinical course of the patient. If the
patient’s general condition and oxygenation status are
satisfactory, test results show a trend toward improvement,
and possible causative agent have decreased, the antibiotic
regimen should be modified to a narrow-spectrum antibiotic
or concomitant treatment with more than one antibiotic
should be discontinued (Fig. 9, Minds recommendation
grade C1).7. Antibiotic therapy and general
management of the elderly pneumonia patients
Summary It is important to adjust the dose of antibiotics prescribed for
elderly pneumonia patients according to their renal function. Estimated glomerular filtration rate (eGFR) calculated by
means of an estimation formula should be used to assess
renal function (Level IVb). Adequate fluid management is important to the treatment
of pneumonia in elderly patients (Minds recommendation
grade B). Poor nutritional status is a risk factor for pneumonia in
the elderly, and thus adequate nutritional management
should be considered (Level I). The management of elderly pneumonia patients requires
consideration of each patient’s general condition and
social background.7.1. Introduction
Many NHCAP patients are elderly and are in poor general
condition due to underlying diseases. Because of reduced
immunocompetence due to aging, poor nutritional status and
immunodeficiency due to the presence and treatment of
underlying diseases and, hypoactivity of the mucociliary
transport system in the airways, a reduced cough reflex,
and other factors, pneumonia in the elderly is often refrac-
tory. In addition, many patients receiving nursing care at
home or in facility are subjected to medical procedures, such
as catheterization that make them more susceptible to
infection. Therefore, treatment of pneumonia in the elderly
requires careful antibiotic therapy and general management.
7.2. Antibiotic therapy in elderly pneumonia patients
Because the renal function of many elderly patients is
reduced, renally excreted drugs often have a prolonged half-
life (T1/2), a higher area under the blood concentration–time
curve (AUC), and a lower urinary excretion rate. Assessment
of the patient’s renal function is necessary before deciding on
the dose of an antibiotic to prescribe, and creatinine clearance
(Ccr) is widely used as an index of renal function in clinical
practice. Because accurate Ccr measurements require urine
collection, estimated creatinine clearance (eCcr) values calcu-
lated from serum creatinine values by the Cockcroft–Gault
formula have been used as an alternative. Cockcroft–Gault formula:
eCcr (mL/dL)¼ (140age)weight (kg)/ [72 serum creatinine
(mg/dL)] (0.85, if female)
However, because the Cockcroft–Gault formula tends to
underestimate Ccr in the elderly in comparison with younger
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(GFR) of Japanese has been proposed [69], and it is in wide-
spread use (Level IVb). Formula for estimating the GFR of Japanese: eGFR (mL/
min/1.73 m2)¼194 serum creatinine1.094  age 0.287
( 0.739, if female)
The nomogram used to obtain the eGFR, which is the value
obtained by using the formula devised for Japanese, is shown
in Supplementary material Fig. S4.
Before prescribing drugs for elderly patients who do not
have standard physique or who have reduced renal function,
their renal function should be assessed based on their eGFR
value without any correction for body surface area (BSA) [70].
eGFR uncorrected for BSA¼eGFRBSA/1.73
Since most antibiotics are excreted renally, dose reduction
is necessary in patients with a decreased GFR. The Guidelines’
recommended administration and dosage of each drug
according to the patient’s renal function are shown in
Supplementary material Table S2 (Note 1: The Ccr values
calculated by means of the Cockcroft–Gault formula and
eGFR values are estimated values. A 24-hour pooled urine
specimen must be used to calculate the Ccr in order to obtain
an accurate glomerular filtration rate. Note 2: The drug doses
for patients with renal impairment specified in the Japanese
Society of Nephrology guidelines [70] are based on the
dosages covered by Japanese National Health Insurance,
and as a result are lower than the doses prescribed for
patients with renal impairment in Western countries.) Refer
to the Sanford Guide to Antimicrobial Therapy 2000 [71] and
other literature for the drug doses recommended for patients
with renal impairment in Western countries.
Therapeutic drug monitoring (TDM) is recommended
whenever the toxic range and therapeutic range of a drug
are close to each other.
7.3. General management of pneumonia in elderly
patients
Antibiotic therapy is the core of treatment for pneumonia.
However, adjunctive therapies as well as general manage-
ment become necessary in elderly patients with underlying
diseases and whose general condition is poor. Attention
should be paid to dehydration, nutritional status, circulatory
function, and oxygenation status [69].1) Fluid management
Dehydration is a problem that requires particular atten-
tion in elderly pneumonia patients. Sweating and hyper-
ventilation due to a fever result in fluid loss, and fluid
intake is sometimes inadequate because of patients’
decreased level of consciousness. When that happens,
adequate fluid therapy becomes necessary (Minds recom-
mendation grade B) [72]. Dehydrated patients exhibit such
clinical manifestations as impaired consciousness, dry
skin, and dry tongue. The diagnosis should be made on
the basis of such clinical findings together with the results
of blood studies such as evidence of hemoconcentration
(high hematocrit and high total protein level) and a high
blood urea nitrogen (BUN) value.Pneumonia in the elderly is usually accompanied by
hypertonic or isotonic dehydration, and whenever it is,
an isotonic solution should be administered according to
the body fluid deficit [73]. Because elderly patients have
little residual cardiac or renal function, care should be
exercised to avoid overinfusion.2) Nutritional management
Poor nutritional status is a risk factor for pneumonia in the
elderly [74], and nutritional management is known to promote
recovery from pneumonia (Level I) [75]. The quality of the diet
of elderly patients is affected by factors such as poor oral
hygiene, taste changes, decreased mobility, and oral medica-
tions, and mental factors such as depression, dementia, and
hypobulia lead to decreased oral intake. Social factors such as
living in a facility, living alone, economic status, and inade-
quate cooking also affect oral intake.
It is important to monitor elderly patients for weight changes
during treatment for pneumonia [76]. A decrease in body
weight by more than 10% of their usual weight has been
found to be associated with a high mortality rate and is
considered serious, and a decrease by 5–10% is considered
potentially serious. The serum albumin level is a useful
index of nutritional status, and the serum albumin levels of
patients with CAP are correlated with their mortality rates
(Level IVb) [77].
Because most NHCAP patients have aspiration pneumonia, an
adequate feeding method for elderly NHCAP patients with
aspiration pneumonia should be selected based on an evalua-
tion of their swallowing ability. Feeding methods for patients
in whom oral intake is poor or impossible include peripheral
venous nutrition, total parenteral nutrition (TPN) via a central
vein, and enteral feeding via a nasogastric tube or a gastro-
stomy tube. The optimal method should be selected in view of
the patient’s condition and social background.3) Respiratory management
The treatment of patients with severe pneumonia or pneu-
monia in patients with underlying lung diseases involves
respiratory management that includes oxygen inhalation
therapy and mechanical ventilation, because they tend to
easily progress to respiratory failure. However, since the
indications for endotracheal intubation and introduction of
mechanical ventilation during the treatment of elderly
patients and patients whose original general condition is
poor depends on various factors, including the patient’s
social background, the physician should take the patient’s
condition, the wishes of the family, and the patient’s wishes
into account when considering intubation or the introduc-
tion of mechanical ventilation. NHCAP patients have a higher
mortality rate than CAP patients, and some reports attribute
their higher mortality rate to background factors, such as
age, complications, and criteria for entering the ICU, rather
than to their course of treatment [61].
8. Aspiration pneumonia
Summary Dysphagia and aspiration are significant risk factors for
NHCAP (Level II)










10Central nerve system (CNS) disease and dementia are
strongly associated with dysphagia, and they are common
underlying diseases in NHCAP patients (Level II) Aspiration pneumonia is more common among HCAP
inpatients than among CAP inpatients (Level IVa). Vaccinations and oral health care are effective in prevent-
ing aspiration pneumonia (Level II, Minds recommenda-
tion grade B)Table 7 – Pathological Conditions That Predispose to
Aspiration (partial revision of the first edition of the JRS
Guidelines for the Management of Hospital-Acquired Pneu-
monia in Adults).
1) Neurological disorders
Cerebrovascular disease (acute phase, chronic phase)
Central neurodegenerative diseases
Parkinson’s disease
Dementia (cerebrovascular, Alzheimer’s type)
2) Bedriddenness (regardless of disease)
3) Oral disorders





Esophageal motility disorders (achalasia, scleroderma)
Malignant tumors
Gastroesophageal reflux disorders (including esophageal hiatal
hernia)
Gastrectomy (total or subtotal gastrectomy)
5) Iatrogenic causes
Sedatives, hypnotics
Drugs that cause dry mouth, e.g., anticholinergic drugs
Tube feedingDrugs that improve the swallowing reflex may be effective
in preventing aspiration pneumonia (Level II, Minds
recommendation grade B); however, percutaneous endo-
scopic gastrostomy (PEG) is not recommended (Level II,
Minds recommendation grade C2)
8.1. Introduction
Pneumonia is the third or fourth highest cause of death in
Japan, and most of the deaths from pneumonia occur in the
elderly population. Japan is facing the advent of an unprece-
dented aging of society, and the field of nursing is rapidly
expanding. In order to meet the demands of the rapidly aging
of society in Japan, we are taking this opportunity to define
and classify NHCAP.
The very old, the so-called old-older subjects of the popula-
tion, now comprise a high percentage of home-care patients
and patients residing in medical and nursing care facilities,
who account for a large proportion of NHCAP patients, and
they are at high risk of aspiration pneumonia. As the
population requiring nursing care increases, the incidence
of aspiration pneumonia is also expected to increase, and the
significance of NHCAP in the healthcare and nursing care
may be evident in future.
8.2. Aspiration as a risk factor for NHCAP
In overseas studies, no sufficient evidence for NHCAP has
been reported. Nursing-home residents have been reported to
be the population at highest risk of hospitalizations for
pneumonia in the U.S., where 33.3 out of 1000 nursing-
home residents per year have required hospitalization for
the treatment of pneumonia, compared with 1.14 out of 1,000
adults living in the community, showing that their risk of
hospitalization is more than 10 times greater [78,79].able 6 – Dysphagia as a risk factor for NHCAP.
) Dysphagia (odds ratio: 2.0) and impossibility of oral intake [78–80] as
) CNS diseases are present as a comorbidity in more than half of NHA
) Lack of assessment of swallowing function as a factor that affects th
) Cerebrovascular disease was found to be a comorbidity in 30% of a g
percentage in the control group [13]
) Impaired consciousness was found to be a comorbidity in approxima
percentage in the control group [13]
) The odds ratio of an impaired consciousness level, a prognostic facto
) CNS diseases and dementia have been found to be underlying diseas
) 19% of a group of NHAP patients in Japan were found to have undergon
) Tube feeding is a background factor in a high proportion of HCAP pat
) Complications of CNS diseases are a background factor in a high perIn addition, 10% to 18% of all patients hospitalized for CAP
in the U.S. are nursing home residents, and the percentage
has been tending to increase [80].
The risk factors for NHAP in nursing homes residents include
dysphagia and impossibility of oral intake (Table 6) [78–80]. It is
also important to note pathological conditions that may
increase patients’ susceptibility to aspiration (Table 7). More
specifically, it has been pointed out that complications of CNS
disease are an underlying disease in more than half of the
cases, and lack of patient evaluations for aspiration is a cause of
treatment inadequacy [28]. Many HCAP patients have cerebro-
vascular disease and impaired consciousness, both of which are
strongly associated with dysphagia, and these disorders may
affect the outcome [13,50] (Level II).
CNS disease and dementia, both of which are strongly
associated with aspiration, are an underlying disease in many
NHAP patients in Japan, and significant numbers of NHAP
patients in Japan have undergone PEG [26]. Similarly, compli-
cations of CNS disease and tube feeding have been found inrisk factors for NHAP
P patients [28]
e outcome of NHAP patients [28]
roup of HCAP patients, approximately 3 times greater than the
tely 20% of a group of HCAP patients, approximately twice the
r in HCAP, is 3.2 times greater than in CAP [50]
es in 31.3% and 59.2%, respectively, of NHAP patients in Japan [26]
e PEG, four times greater than the percentage in the control group [26]
ients in Japan [8]
centage of HCAP cases in Japan [8]
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indicating strong possibility that aspiration, including silent
aspiration such as un-witnessed aspiration during the night,
is involved in the etiology of pneumonia in HCAP patients
[8,81] Thus, difficulty in swallowing and dysphagia, both of
which are strongly associated with aspiration, are the impor-
tant risk factors for HCAP as defined by the ATS/IDSA, and for
NHCAP in Japan (Level II).
8.3. Aspiration pneumonia cases as a proportion
of NHCAP cases
Since pneumonia that results from aspiration is classified
according to its etiology as ‘‘aspiration pneumonia’’, it differs
from pneumonia that is classified as NHCAP because of the
facility where the pneumonia occurred, and because of this
difference, some cases may be diagnosed as both NHCAP and
aspiration pneumonia. There is insufficient evidence in either
Japan or abroad in regard to the proportion of NHCAP cases that
are cases of aspiration pneumonia. Data from Spain indicated
that 20.6% of HCAP patients who require hospitalization haveTable 8 – Procedures for detection of functional dysphagia.
1. Screening methods
Bedside assessment of swallowing function, arterial oxygen saturation m
swallowing test, simple swallowing provocation test, etc.
2. Further swallowing assessment methods
Water swallowing test, videofluoroscopic examination of swallowing, vid
of swallowing, swallowing pressure measurement, simple swallowing pr
pulmonary uptake of a radioisotope, such as indium chloride, dissolved
Fig. 10 – Diagnostic flow chart for aaspiration pneumonia, a clearly higher proportion than among
CAP patients who require hospitalization (3.0%) [13].
Another study reported the presence of comorbidities that
cause aspiration in more than 30% of HCAP patients, and a
multicenter study of hospitalized pneumonia patients in Japan
showed that more than 60% of the patients who had been
hospitalized for CAP had aspiration pneumonia [64]. Thus, based
on this comprehensive assessment, NHCAP cases in Japan are
likely to include many cases of aspiration pneumonia (Level III).
Although the meaning of diagnosing aspiration pneumonia
in NHCAP patients will require validation in the future,
NHCAP is a type of pneumonia that occurs in elderly persons
who have higher ADL disability levels than CAP patients. To
clarify this potential association the detailed diagnosis of
aspiration pneumonia is necessary [12].
8.4. Diagnosis of aspiration pneumonia
Since the only guidelines that clearly define aspiration pneumo-
nia are the JRS Guidelines for the Management of Hospital-Acquired
Pneumonia in Adults, these Guidelines will use their definition ofonitoring during swallowing, repetitive saliva swallowing test, water
eoendoscopic examination of swallowing, laryngoscopic evaluation
ovocation test, swallowing provocation test, examination of
in the mouth the previous night
spiration pulmonary disorders.
Table 9 – Treatment strategies for aspiration pneumonia in NHCAP patients.
1) Antibiotic therapy (with priority given to antibiotics that are effective against oral indigenous bacteria and anaerobic bacteria)
2) PPV injection, if possible (influenza vaccination desired to prevent progression)
3) Oral hygiene and oral healthcare
4) Food intake and swallowing rehabilitation
5) Drug therapy to improve swallowing reflex (ACE inhibitors, cilostazol)
6) Efforts to increase consciousness level (dose reduction and discontinuation of sedatives, hypnotics, etc.)
7) Dose reduction and discontinuation of drugs that cause swallowing difficulty
8) Improvement of the patient’s nutritional state (however, there is no evidence that PEG itself prevents pneumonia)
9) Sleeping position with the patient’s head (upper body) slightly elevated is desirable.
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patients in whom dysphagia and aspiration is known to occur
(or is strongly suspected) (Fig. 10) [3]. It is important to conduct
swallowing function tests as a means of detecting dysphagia and
aspiration, and to determine whether aspiration has occurred
during and after meals. Methods of testing for dysphagia range
from bedside assessments to videofluoroscopic examinations of
swallowing (Table 8). When performed on elderly patients who
require a high level of nursing care, videofluoroscopic examina-
tions of swallowing that are performed with the patient seated
may result in aspiration during or after the examination, and
priority should therefore be given to procedures such as bedside
swallowing function assessments and simple swallowing provo-
cation tests [82]. Further tests can be conducted while monitor-
ing the patient’s condition (Minds recommendation grade B).
Swallowing function assessments and examinations should be
performed in accordance with the healthcare environment at
each nursing care facility.8.5. Treatment (Table 9)
Antibiotic treatment strategies for aspiration pneumonia do not
differ greatly from treatment strategies for NHCAP. Since there
is greater involvement by indigenous oral bacteria and anaero-
bic bacteria in patients with aspiration pneumonia than in
pneumonia patients with no risk of aspiration, antibiotics that
are effective against indigenous oral bacteria and anaerobic
bacteria are given priority when selecting antibiotics to treat
patients with aspiration pneumonia. However, a maximum
effort should be made to identify the causative agents and
select drugs with high activity against them. De-escalation
procedures should be conducted when the causative agents
have been identified and the clinical manifestations have
improved. While the pneumonia of aspiration pneumonia
patients may be cured, their dysphagia does not improve.
Episodes of aspiration may recur during treatment for pneu-
monia, and pneumonia that has improved may become worse
again as a result of recurring aspiration. Dysphagia rehabilita-
tion needs to be provided in parallel with antibiotic treatment
(Level III, Minds recommendation grade B).
There is evidence in Japan that pneumococcal polysacchar-
ide vaccine (PPV) injections are effective in treating NHAP.
PPV injections are also recommended as a means of prevent-
ing aspiration pneumonia in NHCAP patients (Level II, Minds
recommendation grade B) [83].
There is evidence for oral healthcare as another prevention
for aspiration pneumonia (Level II, Minds recommendation
grade B) [84]. Oral healthcare is expected to decrease thenumber of indigenous bacteria and can reduce the incidence
of pneumonia due to unrecognized dysphagia.
PEG is sometimes performed as a means of preventing
aspiration pneumonia, but there is no evidence that it prevents
pneumonia, and the incidence of aspiration pneumonia in PEG
patients is the same as in patients fed through a nasogastric
tube. Thus, PEG is not recommended as a preventative measure
for NHCAP (Level II, Minds recommendation grade C2) [85,86].
ACE inhibitors [87] and cilostazol [88] have been reported to
be effective in preventing pneumonia in patients who have a
history of cerebral infarction and are at high risk of aspira-
tion. Unless the patient is bedridden and has a very low ADL
level, these drugs can be expected to be effective in prevent-
ing aspiration pneumonia in NHCAP patients (however,
they are not covered by Japanese National Health Insurance)
(Level II, Minds recommendation grade B).9. Vaccines
Summary Vaccination of nursing home residents with PPV is useful
in preventing pneumococcal pneumonia and in decreas-
ing the mortality rate (Level II, Minds recommendation
grade B). Vaccination of residents of nursing care facilities for the
elderly with a combination of influenza vaccine and PPV
decreases their hospitalization rate for pneumonia (Level II,
Minds recommendation grade B).
9.1. Introduction
NHCAP is often diagnosed in the elderly population, and vac-
cines play a vital role in preventing respiratory infections in
elderly patients. The two types of vaccines that are being used to
prevent pneumonia in the elderly are PPV and influenza vaccine.
PPV contains the capsular polysaccharides of 23 serotypes of
pneumococci and protects against about 85% of all pneumococ-
cal pneumonia in adults. However, there has been little evidence
regarding the usefulness of PPV or influenza vaccine in relation
to NHCAP.
9.2. Pneumococcal polysaccharide vaccine (PPV)
A large part of the evidence for the usefulness of PPV is based
on its efficacy in preventing invasive pneumococcal infections
in large-scale cohort studies, case-control studies, and meta-
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preventative effects against pneumonia based on large-scale
prospective clinical studies. For example, the results of a meta-
analysis have confirmed the usefulness of PPV against invasive
pneumococcal infections, but the preventive efficacy of PPV
against the development of pneumonia by all causative agents,
including pneumococci, and its effectiveness in lowering
mortality rates have not been clarified [96].
Pneumococci are also significant causative agents of NHCAP.
The incidence of pneumococcal infection is reported to be
particularly high among nursing home residents, among whom
it has been reported to be approximately 14 times higher than
among the elderly residing in the community [97]. The results of
a randomized double-blind placebo controlled study of the
usefulness of PPV in preventing pneumococcal pneumonia that
had been conducted on nursing home residents in Japan were
reported in 2010 [83]. The study revealed that the incidence of
pneumococcal pneumonia and the incidence of pneumonia due
to all causative agents were 63.8% lower and 44.8% lower,
respectively, in the group vaccinated with PPV (502 cases) than
in the group (504 cases) that was not vaccinated with PPV, and
that mortality due to pneumococcal pneumonia was 0% in the
PPV group as opposed to 35.1% in the placebo group (Supple-
mentary material Table S3), indicating PPV was useful in
preventing pneumococcal pneumonia and in decreasing the
mortality rate from pneumococcal pneumonia (Level II). That
was Japan’s first prospective clinical study of PPV vaccination of
nursing home residents, and it was significant in revealing the
importance of PPV in NHCAP. More specifically, mass outbreaks
of pneumococcal infection, including pneumococcal pneumonia,
were found at nursing homes where 5% or less of the residents
had been vaccinated [98–100], and the results showed that there
were no new cases of pneumonia after the residents were
vaccinated, and that the number of the residents who were
infected with MDR pneumococci had decreased [100]. Based on
the above findings, PPV vaccination is recommended for the
prevention of NHCAP, particularly for residents of nursing homes
(Minds recommendation grade B).
9.3. Influenza vaccine
The results of a meta-analysis of studies in regard to the
usefulness of influenza vaccine in elderly patients 65 years of
age and over did not demonstrate that it had the ability to
prevent influenza-like symptoms, the hospitalization rate,
complications, or the mortality rate [101]. However, in view of
the fact that elderly patients and high-risk patients with
underlying diseases who have influenza often have second-
ary bacterial pneumonia, vaccination of NHCAP patients is
critical. Many reports indicate that combined vaccination
with influenza vaccine and PPV is especially useful for elderly
subjects 65 years of age and over. A decrease in the hospita-
lizations for influenza infection, pneumonia, pneumococcal
pneumonia, and invasive pneumococcal infection as well as
an approximately 40% decrease in mortality rate were
observed in a group inoculated with both vaccines in com-
parison with a group that received neither vaccine, and these
results indicate that inoculation with both vaccines had the
added benefit of reducing hospitalizations for influenza or
pneumonia by 10% to 20% and of decreasing hospital deathsby 20–40% [102,103] (Level III). In addition, the hospitalization
for chronic pulmonary diseases in elderly patients inoculated
with either influenza vaccine or PPV alone fell to 52% and
27%, respectively, and mortality rates fell to 70% and 34%,
respectively. However, if both vaccines are administered in
combination, hospitalization and death are reduced to 63%
and 81% [104] (Level III). There have also been reports on the
effects of combined use of both vaccines in Japan [105,106]. In
one study related to NHCAP, 294 bedridden elderly patients
(average age, 81 years; 224 females, 70 males) living at
nursing home facilities received influenza vaccine each year.
The subjects were randomly assigned to a group inoculated
with PPV and a control group that was inoculated with the
influenza vaccine alone, and the study compared the total
number of febrile days, the number of febrile days attribu-
table to an acute respiratory infection, and the number of
days of hospitalization for pneumonia of each patient during
the following year. The data for each parameter measured
showed a decrease of approximately 50% in the group that
received both vaccines in comparison with the control group
inoculated with influenza vaccine alone [105] (Level II).
Consequently, combined inoculation with PPV and influenza
vaccine is recommended for elderly who reside in nursing
facilities (Minds recommendation grade B).
9.4. Conclusion
In Japan, which will continue to have one of the world’s most
rapidly aging societies in the years to come, pneumonia among
the elderly and the prevention of NHCAP are key challenges in
the country’s strategy to cut medical costs. In the U.S., the
Advisory Committee on Immunization Practices (ACIP) has
recommended PPV vaccination of individuals aged 65 years of
age and over, and the United States Centers for Disease Control
and Prevention (CDC) proposed increasing the PPV and influenza
vaccination rate of persons 65 years of age and over to 90% as
one of the ten health goals to be met within the 10-year period
starting in 2000 described in ‘‘Healthy People 2010’’ [107]. Pneu-
movaxs NP is the only PPV that has been approved for use in
Japan. As indicated in Supplementary material Table S4, recipi-
ents of the vaccine are covered by Japanese National Health
Insurance only when it is used for the purpose of ‘‘preventing
pneumococcal infections in post-splenectomy patients 2 years of
age and over’’. As of May 1, 2011, only 444 cities, wards, towns,
and villages in Japan subsidized PPV vaccination (some no longer
do), and the vaccination rate for those 65 years of age and over
remains at 10.55%.
The safety measures investigation group of the pharma-
ceutical safety measures subcommittee of the Ministry of
Health, Labor and Welfare took up the issue of PPV revacci-
nation in Japan and on October 18, 2009 decided that ‘‘when
the need of a particular patient to be revaccinated with PPV is
recognized by a physician, the vaccine may be administered’’
(Supplementary material Table S5). The cost effectiveness
ratio (CER) for extended life expectancy per 100,000 elderly 65
years of age and over, calculations have shown that com-
bined vaccinations with influenza vaccine and PPV would
reduce costs in comparison with vaccination with influenza
vaccine alone (Level III) [108]. Furthermore, because vaccina-
tion of the very old, i.e., those 75 years of age and over, with
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 0 3 – 1 2 6124both vaccines would reduce the overall medical costs of
treatment of pneumonia during the next 12-month period
[106] (Level II), concurrent vaccination with both vaccines is
also superior from the standpoint of cost effectiveness. For
vaccination with PPV and influenza vaccine to become more
widespread in the future, it will be necessary not only to rely
on public funding by local municipalities but for the govern-
ment to take measures as well.Appendix A. Supporting information
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.resinv.2012.
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